Abstract
Daratumumab was associated with an overall response of 23% and a median PFS of 2 months in previously treated patients with WM.
The 2 patients who attained a partial response to daratumumab exhibited higher baseline CD38 median fluorescent intensity in plasma cells.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Humans
-
Receptors, CXCR4
-
Waldenstrom Macroglobulinemia* / drug therapy
Substances
-
Antibodies, Monoclonal
-
Receptors, CXCR4
-
daratumumab